- Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
- Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
- Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
- Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
- Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
- Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
- Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
- Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
- Annovis Bio to Participate in the 139th Yale CEO Summit
- Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.46 |
---|---|
High | 6.31 |
Low | 5.46 |
Bid | 6.20 |
Offer | 6.25 |
Previous close | 6.11 |
Average volume | 1.57m |
---|---|
Shares outstanding | 11.01m |
Free float | 8.30m |
P/E (TTM) | -- |
Market cap | 67.28m USD |
EPS (TTM) | -6.12 USD |
Data delayed at least 15 minutes, as of May 02 2024 00:00 BST.
More ▼